Laurus Labs inks pact with MPP to produce molnupiravir
PTI, Jan 21, 2022, 11:46 AM IST
Image Source: Wikimedia
New Delhi: Drug firm Laurus Labs on Friday said it has inked a pact with Geneva-based MPP (Medicine Patient Pool) for manufacturing the oral COVID-19 antiviral medication molnupiravir.
”We are happy to sign an agreement to manufacture the oral COVID-19 anti-viral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission,” Laurus Labs Founder and CEO Satyanarayana Chava said in a regulatory filing.
Molnupiravir is an orally administered ribonucleoside analog that inhibits the replication of SARS CoV2, and clinical studies have shown this drug to be active against the most common COVID-19 variants.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
CBDT allows tax officials to waive or reduce interest due from assessee
Markets fall in early trade amid unabated foreign fund outflows
New software for fast-tracking project approvals: Karnataka Minister Patil
In-flight passengers can access WiFi services only when allowed, say new rules
SEBI mulls separation of non-regulated activities; ‘cross-default’ definition for debenture trustees
MUST WATCH
Latest Additions
Rebels to be shown the door: Maharashtra BJP chief Bawankule
Rohit Shetty says ‘Singham Again’ his fastest Rs 100 crore film, thanks audience for support
SC junks plea against quashing of LOC issued to ex-house help of Sushant Singh Rajput
People of Wayanad will ask me not to come there often: Priyanka Gandhi
Belagavi: Govt clerk found dead in Tehsildar’s chamber
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.